Brookfield Corporation Completes Annual Filings
BROOKFIELD, NEWS, March 18, 2026 (GLOBE NEWSWIRE) -- Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced that it has filed its 2025 Annual Report on Form 40-F, including its audited financial statements and management’s discussion and analysis for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission ("SEC") on EDGAR and with the Canadian securities regulatory authorities on SEDAR+. These documents are also available at www.brookfield.com and a hard copy will be provided to shareholders free of charge upon request.
About Brookfield Corporation
Brookfield Corporation is a leading global investment firm focused on building long-term wealth for institutions and individuals around the world. We have three core businesses: Alternative Asset Management, Wealth Solutions, and our Operating Businesses which are in renewable power, infrastructure, business and industrial services, and real estate.
We have a track record of delivering 15%+ annualized returns to shareholders for over 30 years, supported by our unrivaled investment and operational experience. Our conservatively managed balance sheet, extensive operational experience, and global sourcing networks allow us to consistently access unique opportunities. At the center of our success is the Brookfield Ecosystem, which is based on the fundamental principle that each group within Brookfield benefits from being part of the broader organization. Brookfield Corporation is publicly traded in New York and Toronto (NYSE: BN, TSX: BN).
For more information, please contact:
| Media: Kerrie McHugh Tel: (212) 618-3469 Email: [email protected] | Investor Relations: Katie Battaglia Tel: (416) 359-8544 Email: [email protected] |
Source: Brookfield Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
- Silexion gets German approval to begin Phase 2/3 pancreatic cancer trial
- Silexion gets German approval for pancreatic cancer trial of SIL204
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share